Medicenna Therapeutics Corp. (MDNA): Price and Financial Metrics
GET POWR RATINGS... FREE!
MDNA Stock Price Chart Interactive Chart >
MDNA Price/Volume Stats
|Current price||$0.73||52-week high||$2.00|
|Prev. close||$0.71||52-week low||$0.40|
|Day high||$0.76||Avg. volume||167,760|
|50-day MA||$0.53||Dividend yield||N/A|
|200-day MA||$0.89||Market Cap||50.93M|
Medicenna Therapeutics Corp. (MDNA) Company Bio
Medicenna Therapeutics Corp. operates as an immuno-oncology company. The Company develops and commercializes therapeutics for the treatment of central nervous system and urological cancers. Medicenna Therapeutics offers its services in Canada.
Most Popular Stories View All
MDNA Latest News Stream
|Loading, please wait...|
MDNA Latest Social Stream
View Full MDNA Social Stream
Latest MDNA News From Around the Web
Below are the latest news stories about MEDICENNA THERAPEUTICS CORP that investors may wish to consider to help them evaluate MDNA as an investment opportunity.
By David Bautz, PhD NASDAQ:MDNA READ THE FULL MDNA RESEARCH REPORT Business Update Update on ABILITY Trial Medicenna Therapeutics Corp. (NASDAQ:MDNA) is currently conducting the Phase 1/2 ABILITY Study (A Beta-only IL-2 ImmunoTherapY Study) of MDNA11 in patients with advanced solid tumors ( NCT05086692 ). In September 2022, the company provided updated anti-tumor activity data from the first four
Medicenna Presents Updated Clinical Data from Dose Escalation Portion of Phase 1/2 ABILITY Study of MDNA11 at the SITC Annual Meeting
- MDNA11’s selectivity and dose-dependent stimulation of anti-cancer immune cells indicates potential for increased anti-tumor activity with continued dose escalation - New data reaffirm MDNA11’s potential to overcome the major safety, pharmacokinetic, and pharmacodynamic shortcomings of IL-2 therapies TORONTO and HOUSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced
We can readily understand why investors are attracted to unprofitable companies. For example, although...
- Results from low and mid-dose escalation cohorts in Phase 1/2 ABILITY study show tumor control in 5 of 14 evaluable patients, including a confirmed partial response in pancreatic cancer - $40 million in cash, cash equivalents, and marketable securities at September 30, 2022, provides runway into Q2 calendar 2024 including completion of ABILITY study - Management hosting conference call and webcast today at 8:30 am ET TORONTO and HOUSTON, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics
In this piece, we will take a look at the top ten penny stocks that are too cheap to ignore. For more stocks, head on over to 5 Penny Stocks To Buy That Are Too Cheap To Ignore. Out of the thousands of stocks that are traded on public markets and are available to retail […]
MDNA Price Returns